Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 12, 2014, Pages 1503-1508

  Han, MeiLan K ^a   Tayob, Nabihah ^a   Murray, Susan ^a   Dransfield, Mark T ^b   Washko, George ^c   Scanlon, Paul D ^d   Criner, Gerard J ^e   Casaburi, Richard ^f   Connett, John ^g   Lazarus, Stephen C ^h   Albert, Richard ⁱ   Woodruff, Prescott ^h   Martinez, Fernando J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b University of Alabama at Birmingham   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MAYO CLINIC   (United States)

^e TEMPLE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Azithromycin; Chronic obstructive pulmonary disease; Exacerbation; Quality of life

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID;

AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; STEROID THERAPY; TREATMENT RESPONSE;

AZITHROMYCIN; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; EXACERBATION; QUALITY OF LIFE;

ADRENAL CORTEX HORMONES; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; AZITHROMYCIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84902665590     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201402-0207OC     Document Type: Article

References (14)

1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al.; COPD Clinical Research Network. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-698.
2. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326.
3. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
4. Lawless J. Negative binomial and mixed Poisson regression. Can J Stat 1987;15:209-225.
5. Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Statist Soc B 2000;62:711-730.
6. Gray FJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
7. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010;23:590-615.
8. Innes AL, Woodruff PG, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV. Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 2006;130:1102-1108. (Pubitemid 44583741)
9. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res 2008;57:497-503.
10. Blasi F, Bonardi D, Aliberti S, Tarsia P, Confalonieri M, Amir O, Carone M, Di Marco F, Centanni S, Guffanti E. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther 2010;23:200-207.
11. Pomares X, Montón C, Espasa M, Casabon J, Monsó E, Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis 2011;6:449-456.
12. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1965;1:775-779.
13. Uzun S, Djamin RS, Kluytmans J, Van't Veer NE, Ermens AA, Pelle AJ, Mulder P, van der Eerden MM, Aerts J. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial. Trials 2012;13:82.
14. Serisier DJ. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013;1:262-274.